(1888PressRelease)
May 01, 2009 - Nymox Pharmaceutical Corporation (NYMX) announced that NX02-0017, the first Phase 3 U.S. clinical trial for NX-1207, the Company's investigational drug for BPH, has been given Investigational Review Board approval to begin.
Screening and enrollment of patients will formally begin in the next 2 weeks. The Company will undertake 2 pivotal Phase 3 U.S. clinical trials for NX-1207, with a total of 1000 patients. The protocol and patient materials have been officially approved by the Investigational Review Board.
Currently there are agreements with 60 investigational sites in the U.S. The Company expects the number of clinical trial sites to be increased to up to 100 investigational sites.
BPH is one of the most commonly diagnosed diseases in the male U.S. population. The condition can seriously impact the health and quality of life of men and can lead to acute urinary retention, incontinence, and other serious consequences.
It is estimated that 50% of men in their 50s have pathological signs of prostatic hyperplasia and from 26 to 46% of men between the ages of 40 to 79 years suffer from moderate to severe urinary problems and symptoms associated with BPH.
http://www.nymox.com/
###
